<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298310</url>
  </required_header>
  <id_info>
    <org_study_id>D2285M00032</org_study_id>
    <secondary_id>Eudract no: 2010-024295-26</secondary_id>
    <nct_id>NCT01298310</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Three-way Cross-over Single Center Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the phenotype in patients with Morton's neuroma and to explore the effect of
      local administration of Xylocaine (lidocaine)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, placebo-controlled, three-way cross-over single center study to
      characterize the phenotype in patients with Morton's Neuroma and to explore the effect of
      local administration of Xylocaine (lidocaine)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)</measure>
    <time_frame>Before and after drug injection at Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)</measure>
    <time_frame>Before and after drug injection at Day 14 (+/-9).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)</measure>
    <time_frame>Before and after drug injection at Day 28 (+/-18).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)</measure>
    <time_frame>After drug injection at Day 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)</measure>
    <time_frame>After drug injection at Day 14 (+/-9).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)</measure>
    <time_frame>After drug injection at Day 28 (+/-18).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of adverse events</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of adverse events</measure>
    <time_frame>Day 14 (+/-9)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of adverse events</measure>
    <time_frame>Day 28 (+/-18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of adverse events</measure>
    <time_frame>Day 43 (+/-32)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Morton's Neuroma</condition>
  <arm_group>
    <arm_group_label>Xylocaine_1mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 injection of Xylocaine (1 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xylocaine_10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 injection of Xylocaine (10 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 injection of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylocaine</intervention_name>
    <description>1 mg/mL solution for injection</description>
    <arm_group_label>Xylocaine_1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylocaine</intervention_name>
    <description>10 mg/mL solution for injection</description>
    <arm_group_label>Xylocaine_10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a clinical diagnosis of Morton's neuroma with symptoms of at least 3
             months duration in one foot (affected foot)

          -  Visual analogue scale (VAS) pain-score of = 40 mm in the painful foot at daily
             activities during the previous week (visit 1)

        Exclusion Criteria:

          -  Allergy to lidocaine

          -  Scars or other dermal conditions on the feet that may interfere with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bror Jonzon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>May 21, 2012</last_update_submitted>
  <last_update_submitted_qc>May 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Morton's neuroma, QST measurements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroma</mesh_term>
    <mesh_term>Morton Neuroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

